Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE1
INTERVENTIONAL
2023-02-28
2023-02-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Mepolizumab in Episodic Angioedema With Eosinophilia
NCT04128371
A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis
NCT02020889
Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)
NCT02836496
Mepo for Eosinophilic Esophagitis (EoE) Study
NCT03656380
Intravenous Mepolizumab In Children With Eosinophilic Esophagitis
NCT00358449
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single Arm
Patients with a biopsy proven diagnosis of eosinophilic fasciitis
Mepolizumab
Mepolizumab (Nucala) 400 mg SC every 4 weeks x 24 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mepolizumab
Mepolizumab (Nucala) 400 mg SC every 4 weeks x 24 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* History and physical examination consistent with EF
* Full thickness skin biopsy characteristic of eosinophilic fascitis and/or MRI radiographic findings characteristic of EF
* Documented peripheral eosinophilia (≥500 microliter)
* Patients who are willing and capable of cooperating to the extent and degree required by the protocol; and
* Patients who read and sign an approved informed consent for this study
Exclusion Criteria
* Known history of adverse reaction to mepolizumab (Nucala)
* Pregnant females
* Females actively trying to conceive
* Vulnerable study population
* Asthma requiring inhaled cortiosteroids
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jason Sluzevich MD
Assistant Professor of Dermatology, College of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jason C Sluzevich, M.D.
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Related Links
Access external resources that provide additional context or updates about the study.
Mayo Clinic Clinical Trials
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
19-011851
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.